Background: Respiratory syncytial virus (RSV) is the primary cause of bronchiolitis and pneumonia in infants and young children worldwide and is often the cause of infections in bone marrow, solid organ transplant, cystic fibrosis and congenital heart disease patients, as well as respiratory tract disease in elderly adults. Treatment options are limited to ribavirin, which is only marginally effective, and passive immunoprophylaxis, which is very expensive. The immunosuppressive agent leflunomide has been shown to exert potent antiviral activity against several herpesviruses and polyomavirus BK. In the current study we have tested the hypothesis that leflunomide exerts antiviral activity against RSV. Methods: Human Hep-2 or small airway epithelial cells were inoculated with RSV and treated with A77 1726, the active metabolite of leflunomide. Syncytia formation was assessed by immunohistochemical staining, and virus yield was measured by plaque assay. Cotton rats were intranasally inoculated with RSV, treated with leflunomide by gavage, and pulmonary viral loads were measured by plaque assay of lung homogenates. 
Respiratory syncytial virus (RSV) is the primary cause of bronchiolitis and pneumonia in infants and young children worldwide. RSV is an opportunistic pathogen that is often unsuspected as the cause of infections in bone marrow as well as solid organ transplant patients, cystic fibrosis patients and congenital heart disease patients [1, 2] and is increasingly being recognized as the cause of respiratory tract disease in elderly, nonimmunocompromised adults [3] . Worldwide, 64 million people are infected annually with RSV, resulting in up to 200,000 deaths [4] . This number, however, may not be a true representation of the occurrence of RSV infections. Routine RSV testing does not occur in children of elementary school age nor in adults or the elderly [5] .
No reliable vaccine against RSV is yet available despite work spanning >40 years, including a failed trial of a formalin-inactivated RSV vaccine in which the disease severity was increased in vaccinated children compared with those treated with a placebo [6, 7] . Palivizumab, a prophylactically administered humanized anti-RSV fusion protein monoclonal antibody, is the most widely used preventive therapy against RSV for premature and high-risk infants [8] . Ribavirin,
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Melinda C Cox Dunn 1, 2 , Deborah A Knight 2, 3 , W James Waldman 2, 3, 4 Introduction the only currently approved antiviral therapy, must be administered by small-particle aerosol for 12-18 h per day for 3-7 days, is only marginally effective against RSV and is not indicated for use in adults [9] . Although palivizumab prophylaxis has been shown to reduce hospitalization days associated with RSV disease, ribavirin treatment has not [10] . In addition, palivizumab is very expensive (approximately 6,100 USD per paediatric patient per season).
Leflunomide [N-(4-trifluoromethylphenyl)-methylisoxazol-4-carboxamide] is an experimental immunosuppressive agent that has been shown to be effective against acute and chronic transplant rejection in animal models [11] [12] [13] and is currently showing promise in Phase 1 clinical trials in transplant recipients [14] . Leflunomide (Arava ® ; Aventis Pharmaceuticals, Inc., Bridgewater, NJ, USA) is currently FDA-approved for the treatment of patients with rheumatoid arthritis, an inflammatory disease, and has recently been approved for treatment of patients as young as 3 years of age [15] . The active metabolite form of leflunomide, A77 1726 [N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotoamide] has two known mechanisms of action: inhibition of protein kinase activity and inhibition of dihydroorotate dehydrogenase, a key enzyme in the biosynthesis of pyrimidine nucleotide triphosphates [16] . Which of these mechanisms is responsible for leflunomide's anti-inflammatory and immunosuppressive properties remains to be fully resolved.
We have previously demonstrated that leflunomide exerts powerful antiviral activity against cytomegalovirus (CMV) [17] , herpes simplex virus [18] and polyomavirus strain BK (BKV) in vitro (GT Meister, unpublished data), and against CMV in vivo [19] . The antiviral activity of this agent is not due to pyrimidine depletion in these viruses since addition of exogenous uridine, which restores pyrimidine nucleotide triphosphate to normal levels, does not reconstitute virus production. In contrast to traditional anti-CMV drugs, leflunomide does not inhibit viral DNA synthesis. Rather this agent inhibits the phosphorylation of several CMV structural phosphoproteins resulting in disruption of virion assembly (GT Meister, unpublished data) [17, 18] . Although no controlled clinical trials have as yet been conducted, two reports (total of 21 patients) by John et al. [20, 21] , as well as several case studies [22] [23] [24] have documented reductions in viral load and improvement of CMV-related symptoms in human transplant recipients suffering CMV disease and treated with leflunomide, including individuals who developed resistance to traditional antiviral drugs or were non-responsive to them initially. In addition, several reports have documented reduction of viral load or complete clearance of BKV and improvement in BKV nephropathy in leflunomide-treated renal transplant recipients [25, 26] . Although none of these studies was controlled, the results do suggest potential clinical utility of leflunomide as an antiviral agent.
In the current investigation we have tested the hypothesis that leflunomide exerts antiviral activity against RSV, a negative-strand RNA virus, and demonstrate that this agent significantly reduces infectious virus production in cultured cells and viral load in RSVinoculated animals.
Methods
Cells and virus
Human epithelial larynx carcinoma cells (HEp-2; generously provided by Joan Durbin, Children's Research Institute, Columbus, OH, USA) were propagated in Dulbecco's minimal essential medium (DMEM; Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA), penicillin G, streptomycin sulfate and amphotericin B. Human small airway epithelial cells (SAEC; Biowhitaker, Walkersville, MD, USA) were propagated in small airway basal medium (Lonza, Chicago, IL, USA) supplemented with additives provided by the manufacturer (bovine pituitary extract, insulin, hydrocortisone, gentamycin, retinoic acid, BSA-FAF, transferrin, T3 hormone, ephinephrine and rhEGF). 2H.9 murine fibroblasts (generously provided by Joan Durbin, Children's Research Institute) were propagated in minimum essential medium supplemented with NaCl, essential and non-essential amino acids, vitamins, Na pyruvate, Na bicarbonate (Sigma Chemical Co., St Louis, MO, USA), 10% fetal bovine serum, penicillin G, streptomycin sulfate and amphotericin B. All cells were maintained at 37°C in a humidified environment of 5% CO 2 /95% air. Just prior to confluence, HEp-2 and H2.9 cultures were passed by brief trypsin digestion at a ratio of 1:10, and SAEC at a ratio of 1:2, with medium changes every 48 h.
HEp-2 cells at 60% confluence were inoculated at low titre with the A2 strain of RSV or each of two low passage clinical isolates, identified as CI 16 and CI 18 (generously provided by Mark R Peeples, Children's Research Institute). Viral adsorption was enhanced by centrifugation (300×g for 30 min) followed by incubation for 30 min at 37°C. The inoculum was removed and cells were rinsed twice with phosphate-buffered saline (PBS) prior to addition of fresh medium. Cultures were incubated at 37°C until 70-80% of the culture shows the formation of syncytia. Cells were scraped from flasks, sonicated in supernatants and centrifuged at 400×g for 10 min to remove cell debris, then at 5,500×g for 50 min to pellet virus. Virus was aliquoted and cryopreserved at -80°C. Viral titre was determined by plaque assay as described below.
Assay of cytopathology and syncytia formation
Monolayers of HEp2 cells or SAEC were pretreated with medium supplemented with 200 µM A77 1726 (generously provided by James W Williams, University of Chicago, Chicago, IL, USA) or culture medium alone for 30 min at 37°C. Pretreatments were removed and monolayers were inoculated with RSV A2 at 0.093 plaque-forming units (pfu)/cell. Viral adsorption was enhanced by centrifugation (300×g for 30 min) followed by incubation for 30 min at 37°C. Cells were washed twice with PBS and fresh media with or without 200 µM A77 1726 was added. The monolayers were examined at 48 h post-inoculation for cytopathic changes using phase contrast microscopy.
Immunohistochemical staining of cell cultures
HEp-2 cells were grown and infected as described above in 8-well chamber slides (Nunc, Rochester, NY, USA). At 48 h post-inoculation, slides were washed in PBS, fixed in 50/50 acetone/methanol for 10 min then air-dried. Slides were rehydrated in tris-buffered saline (TBS) for 5 min then blocked with horse serum in a humidity chamber for 10 min to reduce non-specific binding of antibodies. Slides were incubated (1:1000 dilution) in murine RSV hyperimmune globulin raised against the A2 strain of RSV (generously provided by Joan Durbin, Children's Research Institute) at 37°C for 30 min. Biotinylated horse antimouse antibody (Vector Laboratories, Burlingame, CA, USA) was applied (1:200 dilution) and incubated for 10 min. Slides were then rinsed 3× in TBS and horseradish peroxidase Avidin D (Vector Laboratories) was added (1:500 dilution) for 10 min. Slides were rinsed 3× in TBS, then incubated for 5 min in acetate buffer. Bound antibody was visualized with 9-aminoethylcarbazole substrate and counterstained with haematoxylin. Slides were coverslipped and examined by light microscopy.
Assay of A77 1726 toxicity in vitro
HEp-2 cells were incubated with A77 1726 (200 µM) or culture medium alone at 37°C for 48 h. Following incubation, cells were stained with trypan blue and enumerated to determine cell viability. Additional toxicity assays were conducted by fluorescence flow cytometry. For assay of apoptosis, cells were resuspended in 1X Binding Buffer (Caltag Laboratories, Carlsbad, CA, USA) followed by the addition of 5 µl of APC Annexin V (BD Biosciences, San Jose, CA, USA). Cells were vortexed and incubated at room temperature for 15 min, followed by addition of 100 µl of 1X Binding Buffer. For assay of necrosis, cells were resuspended in PBS and 1 µl of Sytox Red stain (Molecular Probes, Eugene, OR, USA) was added. Cells were incubated at room temperature for 15 min in the dark. Fractions of viable, apoptotic and necrotic cells were quantitated by fluorescence flow cytometry on a FACScaliber flow cytometer (BD Biosciences).
Assay of virus production in cultured cells
HEp-2 cells in 6-well culture plates were inoculated at 60% confluence with RSV strain A2 or each of two low passage clinical isolates (1-2 pfu/cell). Viral adsorption was enhanced by centrifugation of plates (300×g for 30 min) followed by 30 min of incubation at 37°C. Following removal of inocula, monolayers were washed twice with PBS, supplied with fresh culture medium alone, or culture medium supplemented with a pharmacologically relevant range of concentrations of A77 1726 (up to 200 µM). To determine if the effects of A77 1726 were due to pyrimidine depletion, subsets of cultures were additionally treated with 200 µM uridine (Sigma Chemical Co.). As a positive control for inhibition of virus production, RSV-inoculated cells were treated with 200 µM ribavirin (Sigma Chemical Co.). Cultures were incubated for 48 h, harvested by brief trypsin digestion and cryopreserved at -80°C until assayed for virus yield by plaque assay as described below (see Plaque assay of viral load).
Inoculation and treatment of cotton rats
All animal care and procedures were in compliance with Principles of Animal Care (National Society for Medical Research) and the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources/NIH). All studies described herein were approved by the Ohio State University ILACUCs protocol 2005A0112. Pathogen-free cotton rats (Sigmodon hispidus females aged 4-5 weeks; 4 animals/ treatment group; Harlan, Indianapolis, IN, USA) were lightly anesthesized with isoflurane (4.5-5%) and inoculated intranasally with 10 6 pfu of the A2 strain of RSV or low passage clinical isolates (CI 16 or CI 18) of RSV in a total volume of 50 µl of saline. Leflunomide (Sigma Chemical Co.) suspended in 1% carboxymethylcellulose was administered daily by gavage beginning on the day of inoculation (day 0) or delayed until day 3 at doses of 20 or 30 mg/kg/day with or without uridine (500 mg/kg/day by intraperitoneal injection) with a final treatment on day 4 post-inoculation. Controls included RSV-inoculated untreated animals, animals treated with vehicle alone (1% carboxymethylcelluose) daily by gavage, and animals treated with uridine alone intraperitoneally (500 mg/kg/day). Animals were euthanized on day 5 post-inoculation by carbon dioxide asphyxiation. Lungs were excised from each animal under sterile conditions. One lung from each animal was homogenized in a 10% w:v suspension, sonicated to disrupt cells, and cryopreserved at -80°C until assayed for viral load.
Plaque assay of viral load
Serial dilutions of sonicated RSV-inoculated HEp-2 cells or SAEC, or lung homogenates prepared from infected animals were inoculated onto monolayers of 2H.9 murine fibroblasts (generously provided by Joan Durbin, Children's Research Institute) in 6-well culture plates. Viral adsorption was enhanced by centrifugation of plates (300×g for 30 min) followed by 30 min of incubation at 37°C. Following removal of inocula, monolayers were washed twice with PBS, overlaid with methylcellulose supplemented (1.6%) culture medium, and incubated for 48 h. Following incubation monolayers were fixed overnight at room temperature with 10% neutral-buffered formalin. Methylcellulose medium was washed away with water, then plates were air-dried and stained with 10% crystal violet in PBS. Plaques were enumerated under a dissecting microscope. Mean plaque numbers derived from counts of triplicate wells, corrected for dilution factor, were used to determine mean pfu per well, normalized to RSV-inoculated untreated controls for infected cultured cells, or mean pfu per gram of tissue for lung homogenates of infected animals ±1 standard deviation. Statistical differences in viral load between animal treatment groups were determined by Student's t-test.
Assay of leflunomide-associated toxicity in vivo
Four cotton rats were treated by gavage with 30 mg/ kg/day with leflunomide for 5 days as described above. Four untreated animals were included in the study as controls. Animals were weighed and assessed for signs of distress on each treatment day as well as on days 8, 11, 15 and 18. Blood samples were drawn on day 0 prior to initial leflunomide administration, on day 4 after final leflunomide treatment, and on days 14 and 21. Complete blood counts with white blood cell differentials and serum liver panels were perfomed on all blood samples by the Ohio State University Department of Veterinary Biosciences. Animals were euthanized on day 21. Livers were excised, fixed in formalin, sectioned, and stained with haematoxylin/eosin for histological evaluation.
Results
Inhibition of RSV-induced cytopathology and syncytia formation by leflunomide active metabolite A77 1726 
Inhibition of infectious virus production in vitro by leflunomide active metabolite A77 1726
To determine the effect of leflunomide on RSV production in vitro, plaque assays were used to quantitate the virus yield in inoculated HEp-2 cultures incubated in the presence of various concentrations of A77 1726 with or without 200 µM uridine. The data presented in Figure 2 , normalized to untreated controls, show that A77 1726 inhibited the production of infectious RSV in HEp-2 cells in a dose-dependent manner over a pharmacologically relevant range of concentrations. Virus titres generated by HEp-2 cultures (Figure 2 , shown normalized) ranged from approximately 7×10 6 pfu (untreated infected controls) to approximately 6×10 2 pfu (400 µM A77 1726), a reduction in virus production of approximately 4 orders of magnitude. Although higher concentrations of A77 1726 and ribavirin were equally effective at inhibiting the production of infectious virus, A77 1726 showed greater efficacy at lower concentrations. Results of experiments conducted with SAEC were essentially identical to those shown in Figure 2 . As also shown in Figure 2 , the addition of uridine partially restored virus production at lower concentrations of A77 1726, but at higher, effective antiviral A77 1726 concentrations, inhibition of virus production was not reversed by uridine. These results suggest that while pyrimidine depletion may contribute to the antiviral activity of low dose A77 1726, the antiviral mechanism of higher dose A77 1726 is independent of pyrimidine depletion. Experiments conducted with each of two low-passage clinical RSV isolates (CI 16 and CI 18) generated essentially identical results.
Reduction of viral load by leflunomide in vivo
To determine the effect of leflunomide upon RSV viral load in vivo, infectious virus was quantitated by plaque assay of homogenates of lungs recovered from RSV-inoculated cotton rats treated with leflunomide with or without uridine, or vehicle alone. The data presented in Figure 3 demonstrate that leflunomide (30 mg/kg/day) significantly reduced viral load in all CI-18-inoculated animals by >3 orders of magnitude compared with those treated with vehicle alone (P=0.0001). Treatment with 20 mg/kg/day of leflunomide effectively reduced viral load as well (P=0.019), but to a lesser degree. Animals treated additionally with uridine showed no statistically significant difference in plaque reduction compared with those treated with leflunomide alone, implying that the antiviral activity of this agent is independent of pyrimidine depletion in vivo. Similar experiments conducted with the A2 strain of RSV as well as a second clinical isolate (CI 16) generated comparable results.
To simulate a more clinically relevant scenario, we delayed treatment in one group until day 3 postinoculation, when treatment might be sought after symptoms begin in a human infection (Figure 3) . When RSV-inoculated cotton rats were treated with only two doses of leflunomide beginning on day 3 following inoculation, viral load was reduced as effectively as when treatment was begun at the time of inoculation, suggesting that even a short course of leflunomide might effectively control viral load during the period of peak virus titre.
Tolerability of leflunomide in non-RSV-infected cotton rats
All animals in the 21-day toxicity study gained weight regardless of treatment. There were no significant differences in weight gain between animals treated with leflunomide and untreated controls. Likewise, no signs of physical distress were apparent in any of the treated or untreated animals. Blood cell counts and haemoglobin values, as well as serum liver function profiles and liver histology were within normal limits for all animals in both the treatment and the control groups (MCCD et al., data not shown). These results indicate that the leflunomide treatment protocol employed in this investigation was sufficient to control RSV in the absence of the relatively infrequent but well-documented adverse effects of anaemia and hepatotoxicity associated with long-term leflunomide administration.
Discussion
The need for an effective antiviral agent against RSV is urgent. No effective vaccine against RSV is currently available and options for treatment and prophylaxis for RSV are limited. As a preventive treatment, prophylactically administered palivizumab, an RSV fusion protein-specific monoclonal antibody preparation, has been shown to reduce hospitalizations by 55% [8] , but remains very expensive (approximately 6,100 USD per paediatric patient per season). Furthermore, RSV fusion protein mutants resistant to neutralization with palivizumab have recently been recovered in vitro and in immunosuppressed cotton rats treated prophylactically with palivizumab prior to RSV inoculation [27] . The relevance of these findings to palivizumab prophylaxis in humans remains to be determined. The use of ribavirin, the only antiviral drug approved for treatment of RSV disease, has been limited to immunocompromised individuals or to only severe RSV infections because of its limited effectiveness and the technical complications associated with its administration as an aerosol [10] .
In the current investigation we have demonstrated the ability of leflunomide to reduce cytopathology and the formation of syncytia, as well as to reduce infectious virus production in HEp-2 and SAEC cells over a pharmacologically relevant range of concentrations. A77 1726 concentrations employed in these in vitro experiments (0-200 µM) were based upon measurements by Williams et al. [14] of A77 levels (approximately 150 to >400 µM) in sera of human transplant recipients treated with leflunomide as an immunosuppressive agent. Considering the immunosuppressive properties of this agent, in vivo studies were necessary to determine if the antiviral effects of leflunomide against RSV seen in vitro are recapitulated in an animal model and to provide preliminary data for the possible testing of leflunomide in clinical trials against RSV. Although it may seem counterintuitive to suggest that an immunosuppressive agent could reduce viral load, our studies have shown that leflunomide significantly reduces viral load in RSV-infected cotton rats by as much as 4 orders of magnitude compared with untreated infected animals. This reduction was seen in animals inoculated with the standard A2 strain as well as in animals inoculated with each of two low-passage clinical isolates of RSV. Previous pharmacokinetic studies indicate that serum A77 1726 levels produced by the leflunomide doses administered in these experiments were equivalent to generally well-tolerated levels measured in human and kidney transplant recipients [14, 28] . Realistically, in order to be effective in a clinical setting, an antiviral agent must be capable of reducing viral load when administered after the onset of symptoms. Indeed we have shown that even when initiation of treatment was delayed until day 3 post-inoculation, leflunomide was able to reduce viral load as effectively as when treatment was begun concurrent with inoculation.
The specific mechanisms underlying severe lower respiratory tract RSV disease are incompletely resolved, but clearly are complex and multifactorial. Some studies have argued in favour or a dominant role for inflammatory leukocyte infiltration directed by proinflammatory cytokines and chemokines released by RSV-infected epithelial cells and alveolar macrophages, with a prominent role in tissue injury played by neutrophils [29] [30] [31] [32] . Other studies have suggested a prominent role for apoptosis and that severity of disease is dependent primarily upon viral load [33] , an absence of CD8 + T-lymphocytes and natural killer cells [34] , or a dominant Th2 response leading to IgE production and eosinophilia as observed in the catastrophic early formalin-inactivated RSV vaccine trial [6, 7, 35] . Bennett et al. [35] reported that, while RSV bronchiolitis was associated with a greater inflammatory response than non-RSV bronchiolitis, RSV infection was not associated with more severe disease, implying that disease severity is not completely accountable to the intensity of the inflammatory response. However, while not universal, there seems to be some consensus that a disproportionately intense inflammatory response may be a major contributing factor in the consequent tissue damage and airway compromise that characterize severe RSV disease.
As an anti-inflammatory, immunosuppressive agent, leflunomide has been shown to inhibit T-cell activation [16] , B-cell activation and antibody production [28, 36] . It has also been demonstrated to inhibit neutrophil effusion as seen in rheumatoid arthritis patients [37] . Leflunomide has been shown to be effective against acute and chronic transplant rejection in animal models [11] [12] [13] and is currently showing promise as an immunosuppressive agent in clinical trials in human transplant recipients [14] . Regarding the antiviral activity of this agent, we have previously demonstrated graft-preserving immunosuppression and a concurrent 4-6 log reduction in viral load in rat CMV-inoculated rats transplanted with allogeneic hearts and treated with only leflunomide [19] . In addition, generally favourable outcomes reported in several uncontrolled studies of a limited number of human transplant recipients have suggested potential clinical utility of leflunomide in the treatment of CMV and BKV disease [20] [21] [22] [23] [24] [25] [26] 38] . Hence, this potential bifunctionality, including both anti-inflammatory and antiviral properties, suggests that leflunomide may serve to reduce inflammatory cell infiltration that leads to tissue injury and compromised airway function while concurrently reducing viral load.
Evaluation of the potential utility of any new pharmacological intervention must naturally take into consideration drug-associated toxicities. In the case of leflunomide, many years of animal studies as well as clinical experience with leflunomide-treated rheumatoid arthritis patients, organ transplant recipients, and patients treated off-label for viral disease, have facilitated thorough study of potential drug-associated side effects. A representative profile of adverse effects is provided by studies by Williams et al. [14] (53 kidney or liver transplant recipients), Smolen et al. [39] (Phase 3 trial including 133 rheumatoid arthritis patients) and Silverman et al. [40] (27 juvenile rheumatoid arthritis patients). Patient ages ranged from 3 to >60 years and duration of leflunomide treatment ranged from several months to >2 years. The most common potentially serious side effects were anaemia and liver dysfunction, as indicated by increased liver enzyme levels, which were generally transient and improved spontaneously. Additional less common adverse effects included skin rash, gastritis, gastrointestinal bleeding, diarrhoea, nausea and alopecia. Although Williams et al. [14] reported that anaemia was dose limiting in 28% of leflunomidetreated renal transplant recipients, overall frequency of adverse events among the rheumatoid arthritis patients was 5-6% [39, 40] .
Likewise, adverse effects have been rare among transplant recipients treated with leflunomide for CMV disease [14, 39, 40] . However, leflunomide has been shown to be teratogenic when administered to pregnant mice and is hence contraindicated in pregnancy [41] . It should be noted that, with the exception of teratogenicity, the adverse side effects cited above have been observed only in response to long-term leflunomide treatment. Other than mild transient abdominal cramps, no immediate side effects have been observed in patients during the first several days of leflunomide treatment (James W Williams, University of Chicago, personal communication). Indeed, in the current investigation, we have demonstrated that a short course of leflunomide treatment sufficient to significantly reduce viral load in cotton rats has no detectable adverse effect upon blood cell counts, haemoglobin values, liver function or liver histology. These findings, should they translate to humans, will be very encouraging in the consideration of leflunomide treatment as a potential intervention in human RSV disease.
In summary, we have demonstrated that leflunomide exerts potent antiviral activity against RSV in vitro and in vivo, and that its in vivo activity appears to be unrelated to inhibition of pyrimidine synthesis. Taken together with the well-established anti-inflammatory properties of the agent, these findings suggest that a short course of leflunomide treatment, administered at the onset of symptoms might reduce viral load during the period of peak viral titres while concurrently attenuating the destructive inflammatory responses responsible for tissue injury and airway compromise that characterize severe RSV disease. Considering the ease of oral administration, leflunomide has potential as a convenient addition to the growing arsenal of antiviral therapeutics. Sidwell and Barnard [42] have, indeed, suggested that a combination treatment consisting of anti-inflammatory agents and potent antiviral drugs would constitute a fully effective treatment for RSV disease. Hence, leflunomide may well serve as a single drug solution.
